Skip to main content
. 2021 Dec 7;11:168. doi: 10.1186/s13613-021-00955-w

Table 1.

General characteristic data of the study population

Variables No AF
(n = 63)
AF
(n = 16)
P value
Age (years) 65 [59–70] 73 [65–76] 0.026
BMI (kg.m−2) 31.5 [24.9–40.7] 29.3 [26.2–32.8] 0.8
SAPS II score during TTE 32 [21–49] 58 [43–62] 0.001
Male gender (n; %) 40 (65) 14 (88) 0.12
Medical history
 No history 8 (13) 3 (19) 0.68
 Hypertension 31 (50) 12 (75) 0.09
 Diabetes 13 (21) 6 (38) 0.19
 Dyslipidemia 19 (31) 4 (25) 0.76
 Smoking (former or active) 20 (33) 4 (25) 0.76
 Chronic renal disease 5 (8) 2 (12) 0.62
 COPD/asthma 11 (18) 2 (13) 1
 Coronary or peripheral artery disease 15 (24) 5 (32) 0.53
 Obstructive sleep apnea 5 (8) 1 (6) 1
Chronic treatment
 Statine 19 (31) 7 (44) 0.38
 Beta blocker 17 (28) 6 (38) 0.54
 ACE inhibitor 11 (18) 5 (32) 0.30
 ARBs 14 (23) 3 (18) 1
 Diuretic 9 (15) 4 (25) 0.45
 Aspirin 14 (23) 6 (38) 0.33
 Metformin 9 (15) 4 (25) 0.45
Time to first symptom to ICU admission (days) 8 [5–11] 8 [4–14] 0.56
COVID 19 specific treatment (n = 67/89)
 Dexamethasone 49 (81) 11 (74) 0.70
 Remdesevir 3 (5) 0 1
 Tocillizumab 1 (2) 0 1
Atrial fibrillation
 Previous paroxysmal AF 6 (10) 2 (12) 0.61
 Occurrence of AF, (days) 7 [2–11]
 CHA2DS2-VASc 2 [1–3] 3 [1–4] 0.20
Outcome
 Arterial thromboembolic events 0 1 (6)* 0.21
 Length under MV, days 17 [10–24] 28 [16–44]  < 0.001
 Mortality at 30-days 14 (22) 7 (43) 0.11
 ICU discharge, days 61 (93) 13 (82) 0.06
 Length of stay in ICU, days 12 [5–21] 25 [14–33]  < 0.001

Bold indicates P < 0.05

Continuous variables are expressed as median [interquartile range] and categorical variables as number (percentage)

ACE angiotensin-converting enzyme, AF atrial fibrillation, ARBs angiotensin II receptor blockers, BMI body mass index, COPD chronic obstructive pulmonary disease, ICU intensive care unit, MV mechanical ventilation, SAP systolic arterial pressure, SAPS simplified acute physiology score, TTE transthoracic echocardiography

*ischemic stroke